Trial · NCT00281021
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
NCT00281021, Phase 2, Terminated, University of Louisville; results first posted 2014-11-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer. Trials, record NCT00281021. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00281021
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
- NCT number
- NCT00281021
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 26 participants, actual
- Lead sponsor
- University of Louisville
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- Erlotinib plus Digoxin
- First posted
- 2006-01-24
- Last updated
- 2018-03-29
- Results first posted
- 2014-11-10
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest & Abdomen. | Measured every 6 weeks after baseline until disease progression, an average of 3 months |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest & Abdomen. | Measured every 6 weeks after baseline until disease progression, an average of 3 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest & Abdomen. | Erlotinib and Digoxin | Partial Response | 1 | participants | |
| Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest & Abdomen. | Erlotinib and Digoxin | Stable Disease | 9 | participants | |
| Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest & Abdomen. | Erlotinib and Digoxin | Progressive Disease | 14 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Erlotinib and Digoxin | 26 | |
| Overall Study | COMPLETED | Erlotinib and Digoxin | 24 | |
| Overall Study | NOT COMPLETED | Erlotinib and Digoxin | 2 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Erlotinib and Digoxin | 13 | 24 | |
| other | Fatigue | General disorders | Erlotinib and Digoxin | 5 | 24 | |
| other | Rash | General disorders | Erlotinib and Digoxin | 10 | 24 | |
| other | Nausea | Gastrointestinal disorders | Erlotinib and Digoxin | 3 | 24 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Erlotinib and Digoxin | 2 | 24 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Erlotinib and Digoxin | ||
| Total, other adverse events | Erlotinib and Digoxin | 20 | 24 |
| Total, serious adverse events | Erlotinib and Digoxin | 0 | 24 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00281021
GET https://conductscience.org/api/trials/v1/NCT00281021/registered